Waldenstrom Macroglobulinemia Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drugs (Rituximab, Zanubrutinib, Ibrutinib,  Ventoclax, Cladribine, Lenalidomide, Pomalidomide, Carfilzomib, Bortezomib, Daratumumab), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others), and Region Forecast 2020-2031

Waldenstrom Macroglobulinemia Treatment Market size was valued at US$ 174.7 million in 2024 and is expected to reach US$ 275.0 million by 2031, growing at a significant CAGR of 6.7% from 2025-2031. Waldenström macroglobulinemia (WM) is a rare type of blood cancer that affects white blood cells. It is characterized by the production of an abnormal protein called IgM, which can cause various symptoms, including fatigue, weakness, bleeding, and swelling. WM is slow-growing cancer; most patients live for several years after diagnosis. However, the disease can eventually become life-threatening. The prevalence of WM is estimated to be about 1 in 100,000 people. The average age of diagnosis is 65 years, and men are slightly more likely to be affected than women.

The cause of WM is unknown, but it is thought to be a combination of genetic and environmental factors. There is no cure for WM; currently, there are various treatments available to help control the disease. The most common treatments include chemotherapy and radiation therapy. Other treatments that may be used include stem cell transplantation and targeted therapy. The treatment of WM can be challenging, and there are several side effects that can occur. These side effects can vary depending on the treatment type used. Some common side effects of chemotherapy include fatigue, nausea, vomiting, and hair loss. Radiation therapy can cause side effects such as skin burns, fatigue, and diarrhoea. Stem cell transplantation is a major surgery that carries a risk of complications, such as infection and graft-versus-host disease. The mortality rate for WM is about 50% at ten years. However, the survival rate has improved in recent years due to advances in treatment.

Key Developments

• In Jan 2022, BeiGene announced the acceptance of its NDA application in China for Brukinsa for the treatment of waldenstrom’s macroglobulinemia (WM).